This article was originally published in Pharmaceutical Approvals Monthly
Joint venture responds August 21 to FDA's June 23 complete response letter for the lymphocytic leukemia treatment. The response includes additional analysis and follow-up data. The alemtuzumab BLA, submitted in December 1999, may be reviewed by FDA's Oncologic Drugs Advisory Committee at its December meetin
You may also be interested in...
A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.